JP2024543209A5 - - Google Patents
Info
- Publication number
- JP2024543209A5 JP2024543209A5 JP2024532776A JP2024532776A JP2024543209A5 JP 2024543209 A5 JP2024543209 A5 JP 2024543209A5 JP 2024532776 A JP2024532776 A JP 2024532776A JP 2024532776 A JP2024532776 A JP 2024532776A JP 2024543209 A5 JP2024543209 A5 JP 2024543209A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- subject
- variant
- seq
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163284978P | 2021-12-01 | 2021-12-01 | |
| US63/284,978 | 2021-12-01 | ||
| US202263348201P | 2022-06-02 | 2022-06-02 | |
| US63/348,201 | 2022-06-02 | ||
| PCT/US2022/080728 WO2023102463A1 (en) | 2021-12-01 | 2022-12-01 | Methods of using interleukin-2 agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024543209A JP2024543209A (ja) | 2024-11-19 |
| JP2024543209A5 true JP2024543209A5 (https=) | 2025-12-08 |
Family
ID=84981477
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024532776A Pending JP2024543209A (ja) | 2021-12-01 | 2022-12-01 | インターロイキン－２剤の使用方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240041981A1 (https=) |
| EP (1) | EP4440598A1 (https=) |
| JP (1) | JP2024543209A (https=) |
| KR (1) | KR20250169356A (https=) |
| CN (1) | CN120131911A (https=) |
| AU (1) | AU2022399832A1 (https=) |
| CA (1) | CA3238574A1 (https=) |
| MX (1) | MX2024006746A (https=) |
| TW (1) | TW202333772A (https=) |
| WO (1) | WO2023102463A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH12022550165A1 (en) | 2019-07-26 | 2023-05-08 | Visterra Inc | Interleukin-2 agents and uses thereof |
| US12098178B2 (en) | 2020-12-04 | 2024-09-24 | Visterra, Inc. | Methods of using interleukin-2 agents |
| WO2025221954A1 (en) * | 2024-04-17 | 2025-10-23 | Visterra, Inc. | Use of il-2 variant for treating kidney transplant rejection |
| CN119638850A (zh) * | 2024-11-07 | 2025-03-18 | 浙江大学 | 双特异性细胞因子融合蛋白及其应用 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| EP0436597B1 (en) | 1988-09-02 | 1997-04-02 | Protein Engineering Corporation | Generation and selection of recombinant varied binding proteins |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8905669D0 (en) | 1989-03-13 | 1989-04-26 | Celltech Ltd | Modified antibodies |
| WO1991000906A1 (en) | 1989-07-12 | 1991-01-24 | Genetics Institute, Inc. | Chimeric and transgenic animals capable of producing human antibodies |
| DE69120146T2 (de) | 1990-01-12 | 1996-12-12 | Cell Genesys Inc | Erzeugung xenogener antikörper |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| DK0585287T3 (da) | 1990-07-10 | 2000-04-17 | Cambridge Antibody Tech | Fremgangsmåde til fremstilling af specifikke bindingsparelementer |
| ATE158021T1 (de) | 1990-08-29 | 1997-09-15 | Genpharm Int | Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper |
| DE69133557D1 (de) | 1990-08-29 | 2007-03-15 | Pharming Intellectual Pty Bv | Homologe rekombination in säugetier-zellen |
| CA2095633C (en) | 1990-12-03 | 2003-02-04 | Lisa J. Garrard | Enrichment method for variant proteins with altered binding properties |
| EP1820858B1 (en) | 1991-03-01 | 2009-08-12 | Dyax Corporation | Chimeric protein comprising micro-protein having two or more disulfide bonds and embodiments thereof |
| ATE414768T1 (de) | 1991-04-10 | 2008-12-15 | Scripps Research Inst | Bibliotheken heterodimerer rezeptoren mittels phagemiden |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
| DK1621554T4 (da) | 1992-08-21 | 2012-12-17 | Univ Bruxelles | Immunoglobuliner blottet for lette kæder |
| US6955807B1 (en) * | 1998-05-15 | 2005-10-18 | Bayer Pharmaceuticals Corporation | IL-2 selective agonists and antagonists |
| IT1395574B1 (it) | 2009-09-14 | 2012-10-16 | Guala Dispensing Spa | Dispositivo di erogazione |
| US9580486B2 (en) * | 2013-03-14 | 2017-02-28 | Amgen Inc. | Interleukin-2 muteins for the expansion of T-regulatory cells |
| CA2982362A1 (en) * | 2015-04-10 | 2016-10-13 | Amgen Inc. | Interleukin-2 muteins for the expansion of t-regulatory cells |
| JP7422480B2 (ja) | 2016-05-04 | 2024-01-26 | アムジエン・インコーポレーテツド | 制御性ｔ細胞の増殖のためのインターロイキン－２変異タンパク質 |
| HRP20260151T1 (hr) | 2016-08-02 | 2026-03-27 | Visterra, Inc. | Modificirani polipeptidi i njihova uporaba |
| JP2020530280A (ja) * | 2017-07-03 | 2020-10-22 | トルク セラピューティクス， インコーポレイテッド | 免疫刺激性融合分子およびその使用 |
| PH12022550165A1 (en) | 2019-07-26 | 2023-05-08 | Visterra Inc | Interleukin-2 agents and uses thereof |
-
2022
- 2022-12-01 AU AU2022399832A patent/AU2022399832A1/en active Pending
- 2022-12-01 CN CN202510086918.0A patent/CN120131911A/zh active Pending
- 2022-12-01 US US18/060,725 patent/US20240041981A1/en active Pending
- 2022-12-01 KR KR1020247021478A patent/KR20250169356A/ko active Pending
- 2022-12-01 EP EP22843966.7A patent/EP4440598A1/en active Pending
- 2022-12-01 TW TW111146169A patent/TW202333772A/zh unknown
- 2022-12-01 MX MX2024006746A patent/MX2024006746A/es unknown
- 2022-12-01 JP JP2024532776A patent/JP2024543209A/ja active Pending
- 2022-12-01 CA CA3238574A patent/CA3238574A1/en active Pending
- 2022-12-01 WO PCT/US2022/080728 patent/WO2023102463A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024543209A5 (https=) | ||
| JP2024502708A5 (https=) | ||
| CA2122340C (en) | Treating retinal neuronal disorders by the application of insulin-like growth factors and analogs | |
| JP2019507589A5 (https=) | ||
| JP2026053628A (ja) | 抗炎症剤に連結されたｅｃｍ親和性ペプチドを用いて炎症性状態および自己免疫状態を処置するための方法および組成物 | |
| KR20080071119A (ko) | 알부민 융합 단백질 | |
| JP2011502479A5 (https=) | ||
| CN107446051B9 (zh) | 靶向cd19的嵌合抗原受体及其用途 | |
| JP2023528207A5 (https=) | ||
| JP2022524078A (ja) | 深部組織浸透性ｃ５阻害剤としてのジルコプラン | |
| JP2024540275A5 (https=) | ||
| WO2018236931A1 (en) | Peptide compositions and related methods | |
| TW202104274A (zh) | 用於治療ｈｉｖ感染之三特異性及／或三價結合蛋白 | |
| WO2020041142A1 (en) | Treating spinal cord injury (sci) and brain injury using gsx1 | |
| AU2005298245B2 (en) | A thymus-specific protein | |
| EP1567545B1 (en) | Peptides and their use in the treatment of central nervous system damage | |
| TW200846366A (en) | Agent for suppressing rejection in organ transplantation comprising anti-hmgb-1 antibody | |
| US20140288010A1 (en) | Compositions and Methods for Increasing Stem Cell Survival | |
| AU2010328359A1 (en) | Anti-inflammatory antibodies and uses therefor | |
| JP2995860B2 (ja) | 新規ペプチド | |
| JPH07503024A (ja) | トロンボスポンジン−ｃｄ３６相互作用の変調 | |
| CN107428811A (zh) | 用于治疗和/或诊断阿尔茨海默氏痴呆症的特异性结合A‑β‑物类的肽 | |
| US20100172909A1 (en) | Cerebral edema suppressant | |
| JPWO2022071435A5 (https=) | ||
| JP2023532732A5 (https=) |